HR 853
117th Congress
House
Health
Drug therapy
Health care costs and insurance
Inflation and prices
Prescription drugs
Closing Loopholes for Orphan Drugs Act
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 5, 2021
Referred to the Subcommittee on Health.
Feb 4, 2021
Referred to the House Committee on Energy and Commerce.
Feb 4, 2021
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Closing Loopholes for Orphan Drugs Act
This bill revises the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (i.e., drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.
What's happening now
Referred to the Subcommittee on Health.
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cite this page
U.S. Congress. (2026). H.R. 853: Closing Loopholes for Orphan Drugs Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-853/
"H.R. 853: Closing Loopholes for Orphan Drugs Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-853/.
H.R. 853, 117th Cong. (2026), https://openamerica.io/bill/117-HR-853/.
[H.R. 853: Closing Loopholes for Orphan Drugs Act](https://openamerica.io/bill/117-HR-853/)